Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 36

recruiting
3 987
countries
28
conditions
2 109

951 trials match your criteria

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal polysaccharide serotype 1

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate

Escherichia infection

Not recruiting

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug
Countries:PolandPoland
  • Participants:65+ years · Healthy volunteers
  • Substances:ECOO15

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Older

Not recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Long-Term Safety and Efficacy of Lunsekimig for Adults with Chronic Rhinosinusitis with Nasal Polyps

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium chloride solution 0.9%

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:PolandPoland
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)

Paranasal sinus inflammation+1

Not recruiting

Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Brensocatib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.